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Albert Christersson*, Bengt Sandén and Sune LarssonAbstract
Background: Recombinant human platelet-derived growth factor BB (rhPDGF-BB) combined with an osteoconductive
scaffold (β-TCP) has been demonstrated to increase bone formation, but rhPDGF-BB has not been studied in
human fractures. The purpose of this study was to evaluate the safety and potential use of locally administered
rhPDGF-BB/β-TCP (Augment®) in acute wrist fractures.
Methods: Forty patients with unstable distal radial fracture were randomized to closed reduction and external fixation
alone (n = 20) or combined with injection of rhPDGF-BB/β-TCP (Augment®) into the fracture (n = 20). All patients were
followed for 24 weeks. Outcome was based on adverse events, fracture displacement on radiographs, fracture healing,
range of motion, grip strength, pain, and the disability of the arm, shoulder and hand (DASH) score.
Results: There were no serious adverse events in the study, but the pin tract infection rate was significantly lower in
the Augment® group. There was no difference between the groups in fracture healing time, based on number of
healed cortices or fracture displacement. The Augment® group had an early temporary significant decrease in wrist
flexion, but no difference in range of motion at 24 weeks. There were no differences between the two treatment
groups for any other outcome variables.
Conclusion: rhPDGF-BB/β-TCP (Augment®) is safe and convenient for local administration into wrist fractures. In this
pilot study, we could not detect any reduced healing time in the Augment® group although potential efficacy should
be addressed in larger studies.
Clinical trial registration number: The clinical trial registration number for the study protocol is BMPI-2014-02-E.
Keywords: Distal radius fracture, External fixation, PDGF, Calcium phosphate, Radiographic evaluation, Clinical
evaluation, Prospective, RandomizedBackground
Platelet-derived growth factor (PDGF) has several func-
tions in humans including promotion of angiogenesis
and wound healing [1-3]. Both in vitro and in vivo pre-
clinical studies have shown that recombinant human
platelet-derived growth factor BB (rhPDGF-BB) stimu-
lates bone formation [4,5]. It has also been demonstrated
that application of rhPDGF-BB has a stimulatory effect
on fracture healing in rabbit tibia fractures [6] as well as
in tibial fracture models in rats [7-9]. So far, there are
few clinical studies assessing the potential stimulating* Correspondence: albert.christersson@akademiska.se
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unless otherwise stated.effect of PDGF on bone regeneration in humans. Local
application of rhPDGF-BB gave a significant gain in
bone formation in advanced periodontal osseous defects
[10]. In studies on foot fusions, rhPDGF-BB was found
to represent a safe and efficacious treatment alternative
to autologous bone graft [11-13]. There are no available
studies in humans where an rhPDGF-BB containing
matrix has been used in acute fractures.
The primary aim of the present prospective random-
ized controlled feasibility study was to assess the safety
and utility of rhPDGF-BB (Augment®) when applied lo-
cally in acute distal radius fractures. Our hypothesis was
that local application of rhPDGF-BB (Augment®) into
distal radius fractures is a safe and utile procedure.ntral. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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Forty consecutive patients aged 50 years or older, with a
displaced unstable distal radius fracture, not suitable for
conservative treatment, were included. All patients were
treated at the Department of Orthopedics, Uppsala
University Hospital, Sweden. Exclusion criteria were
high-energy fractures, open or intraarticular displaced
fractures, soft tissue infection at the operative site, previ-
ous wrist fracture on either side, bilateral fractures, frac-
ture involving the shaft of the radius, or ulna other than
a simple fracture through the styloid, patient currently
undergoing radiotherapy or chemotherapy, patient with
metabolic disorder or chronic medication known to ad-
versely affect the skeleton, or physically or mentally
compromised patients.
The study was approved by the local ethical committee
of Uppsala University. All patients gave written informed
consent before entering into the study.
After signing the informed consent form, each patient
underwent treatment that included closed reduction and a
bridging external fixation (Hoffman Compact II, Stryker
AB, Malmö, Sweden) under general anesthesia. All pa-
tients were operated on by the authors. All patients were
given a single dose of 2 g isoxazolyl penicillin before sur-
gery as prophylaxis. Two Apex™ screws (APEX Fasteners
Inc., Monrovia, CA, USA) were placed from the dorsal
side into the radius and two Apex™ screws were placed
from the dorso-radial side into the second metacarpal
bone. After the external fixation had been mounted, the
fracture was reduced under fluoroscopic guidance into an
anatomic or near anatomic position after which the frame
was locked. K-wires for temporary fixation were not used
in any case, mainly because no severely displaced intraarti-
cular fractures were included. The patients were then ran-
domized in the operating room to one of two treatment
groups using a closed envelope technique with strictly
sealed, numbered, and not transparent envelopes.
The two treatment groups consisted of one group where
in addition to the external fixation and closed reduction,
Augment® (rhPDGF-BB/β-TCP) (BioMimetic Therapeutics
Inc., Franklin, TN, USA) was applied locally into the frac-
ture void while the controls were treated with external fix-
ation alone. Twenty patients were allocated to each
treatment group. In the Augment® group, the first ten pa-
tients were treated with Augment® Bone Graft, while the
last ten patients were treated with Augment® Injectable.
Augment® Bone Graft and Augment® Injectable are
two separate formulations that combine rhPDGF-BB
(0.3 mg/ml) with a synthetic bone matrix consisting of
β-tricalcium phosphate (β-TCP). Augment® Injectable also
contains soluble type I collagen (Kensey Nash Corp.; Exton,
PA, USA), which makes it injectable through a canula.
In the Augment® group, a 1-cm dorsal incision over the
fracture site was made. Using an elevator, the cancellousbone inside the fracture void was slightly impacted to allow
for insertion of 5 ml of Augment® Bone Graft in the frac-
ture void in the first cohort or 3 ml of Augment® Injectable
in the last cohort. In both groups, the amount of rhPDGF-
BB delivered to each patient was 0.3 mg. The skin was
closed with a single suture and covered with sterile gauze.
Pin sites were also covered with sterile gauze, similar in
both treatment groups, with change of gauze twice a week.
Radiographs including AP and lateral views were taken
postoperatively and at follow up at 1, 3, 6, 12, and 24 weeks
of the injured wrist while radiographs of the uninjured
wrist were taken for comparative reasons at 3 weeks. Bone
mineral density was measured by DEXA (DPX-L, Lunar
Co, Madison, WI, USA) on the uninjured wrist within
4 weeks. A research physiotherapist, who was not involved
in the treatment of the patients, measured range of mo-
tion (ROM), grip strength, pin site condition, local signs of
inflammation including redness and swelling, pain (VAS
scale), and DASH-score according to a specific protocol at
all visits. Active range of motion was measured in both
wrists using a goniometer with the unaffected wrist used
as the normal range for each patient. Grip strength was
assessed based on the average of three measurements on
each occasion using a Jamar dynamometer [14]. In
addition, all patients were seen by another physiotherapist
at the department directly after surgery, as well as on
follow-up visits during the course of treatment, to get in-
structions related to their rehabilitation. Pin site condition
was assessed twice a week by a nurse [15]. The external
fixation was removed at 6 weeks in all patients.
All radiographs were examined by two independent
assessors according to a predefined protocol that in-
cluded measurement of the dorsal and radial angulation
and axial compression. As the β-TCP granules in Aug-
ment® makes the product somewhat visible on radio-
graphs, it was not possible to ensure blinding of the two
assessors of the radiographs although they were blinded
with respect to all clinical variables. Fracture healing was
assessed at 6, 12, and 24 weeks. A fracture was defined
as healed when three cortices were bridged by bone.
Statistics
The independent t-test was used to compare the two
groups for baseline characteristics and range of motion.
Confidence interval (95%) was used to compare the
radiographic results, pain, DASH, and grip strength. Chi
square test was used for comparison of proportions, ex-
cept for rate of pin infection where Fisher’s exact test
was used. A p value less than 0.05 was considered as sta-
tistically significant.
Results
There were no significant differences at enrollment be-
tween the two treatment groups with regard to age,
Figure 1 Postoperative radiograph and 6 months after.
Postoperative radiograph after external fixation and dorsal injection
of Augment® into the fracture gap (A). At 6 months, all Augment®
has resolved (B).
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fractured side, hand dominance, or bone mineral density.
Neither were there any differences between treatment
groups regarding proportion of different fracture types
(Table 1). The pre- and postoperative radiographs re-
vealed no significant difference in fracture position be-
tween the two treatment groups. This means that the
two groups had a very comparable starting point with
respect not only to demographics but also to the radio-
logical fracture variables.
All 40 patients completed the follow-up according to
the protocol. There were no serious adverse events dur-
ing the study period. In almost all patients in the Aug-
ment® group, the postoperative radiographs revealed
small amounts of β-TCP particles in the soft tissue on
the dorsal side. In Augment® Injectable patients, but not
in Augment® Bone Graft patients, there was also leakage
of material into the volar soft tissues as assessed on the
postoperative radiographs. Almost all Augment®,
whether contained in the fracture void or in the
surrounding soft tissues, was resorbed at 24 weeks
(Figure 1A,B).
There were three shoulder-hand-finger syndromes in
the Augment® group and one in the control group, but this
difference was not significant. All patients recovered fol-
lowing physiotherapy. No infections or signs of inflamma-
tion were observed at the fracture site in any of the
Augment® patients. There were two pin infections in one
patient in the Augment® group, while in the control group,
pin infections occurred around 18/80 (22.5%) pins in ten







Gender (M/F) 1/19 1/19 NS
Age (years) 65 ± 9.3 65 ± 8.2 NS
Length (cm) 166 ± 5.1 166 ± 7.4 NS
Weight (kg) 65 ± 10.2 71 ± 13.6 NS
Injured side (dx/sin) 8/12 6/14 NS
Injured side (dominant/nondominant) 8/12 6/14 NS
BMD (T-score intact wrist) −1.66 ± 1.11 −1.14 ± 1.18 NS
Smoking (yes/no) 2/18 2/18 NS
Fracture classification (AO):
23A3.2 3 3 NS
23A3.3 0 2 NS
23C2.1 7 5 NS
23C2.2 8 5 NS
23C3.2 2 5 NS
Time in ex fix, days (range) 42 (38–45) 42 (37–44) NSpatients). No fixation pin had to be prematurely removed,
and all pin-related infections healed uneventfully following
oral antibiotics or pin removal at 6 weeks.
All fractures healed during the period of follow-up. At
6 weeks, no fracture, in any of the two groups, was radio-
logically healed according to the criteria used in the study,
i.e., three cortices with bridging bone. At 12 weeks, 9 frac-
tures in the Augment® group and 13 fractures in the con-
trol group were radiologically healed, while all fractures
were radiologically healed at the final follow-up at
24 weeks. There were no significant differences between
the two groups with respect to fracture position at
any follow-up visit or at the final follow-up at 24 weeks
(Figures 2, 3 and 4).
Clinical assessment revealed that the patients treated
with Augment® had significantly less wrist flexion at 6
and 12 weeks, but not at 24 weeks, compared to the
control group, while there were no differences between
the two treatment groups for any of the other wrist
movements (Table 2).
No statistically significant differences in DASH score
or pain were found between the two treatment groups at
any time point. DASH score decreased in both groups
over time, and at 6 months, the average DASH score
was 6.8 in the Augment® group and 6.6 in the control
group (Figure 5). There was no significant difference in
grip strength between the treatment groups at any time
point. At 24 weeks, grip strength was still reduced on
average 41% for Augment® patients and 39% for controls
(about 10 kg in absolute value) when compared to the





























Uninjured Acute Postop        1              3               6 12 24 (weeks)
     side
(degrees °)
Figure 2 Dorsal angulation on radiographs (mean with 95% CI).
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42 versus 29 min, when compared to the control group
(p < 0.0001), i.e., application of Augment® added on aver-
age 13 min to the procedure, with no significant differ-






















Uninjured Acute Postop        1  
     side
Figure 3 Radial angulation on radiographs (mean with 95% CI).Discussion
The main findings of this study were that all fractures
healed both radiographically and clinically without
differences between the treatment groups, there were
no serious adverse events in any of the patients, and
Augment® (rhPDGF-BB/β-TCP) could be handled andControl
Augment®






















Uninjured    Acute    Postop         1 3 6 12 24
     side
Figure 4 Axial compression on radiographs (mean with 95% CI).
Table 2 Decrease in range of motion (degrees) of the radio
carpal joint compared to uninjured side (mean and
standard deviation)
Augment® Controls p
Wrist flexion 6 weeks −46 ± 12 −36 ± 9 0.006
12 weeks −35 ± 11 −23 ± 14 0.007
24 weeks −24 ± 9 −16 ± 12 NS
Wrist extension 6 weeks −57 ± 11 −50 ± 17 NS
12 weeks −22 ± 14 −16 ± 12 NS
24 weeks −10 ± 11 −9 ± 8 NS
Radial deviation 6 weeks −23 ± 8 −22 ± 10 NS
12 weeks −12 ± 8 −8 ± 9 NS
24 weeks −6 ± 6 −3 ± 9 NS
Ulnar deviation 6 weeks −23 ± 9 −18 ± 8 NS
12 weeks −16 ± 9 −12 ± 9 NS
24 weeks −11 ± 8 −8 ± 8 NS
Supination 1 weeks −33 ± 20 −31 ± 19 NS
3 weeks −39 ± 21 −36 ± 22 NS
6 weeks −43 ± 21 −37 ± 22 NS
12 weeks −24 ± 18 −21 ± 16 NS
24 weeks −8 ± 8 −9 ± 8 NS
Pronation 1 weeks −27 ± 18 −24 ± 15 NS
3 weeks −24 ± 19 −24 ± 14 NS
6 weeks −16 ± 15 −12 ± 11 NS
12 weeks −11 ± 11 −4 ± 8 NS
24 weeks −4 ± 6 −3 ± 7 NS
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handling perspective, Augment® Injectable was relatively
easier to use as it could be injected into the fracture void
compared to Augment® Bone Graft, where the technique
used for application had to be adjusted to allow ad-
equate placement of the compound containing β-TCP
particles. The study was a pilot clinical trial and therefore
not powered to measure efficacy. With the present num-
ber of patients, the observed standard deviation and a stat-
istical power of 80%, an average difference of 4° in dorsal
angulation between the groups could have been detected.
A difference of 4° in dorsal angulation can be challenged
as to whether or not it is of clinical importance. Accord-
ingly, it had been possible to detect a clinical significant
difference in dorsal angulation.
In animal studies, as well as in periodontal bony de-
fects in humans, it has been shown that recombinant
PDGF accelerates bone formation when compared to
controls [6-10]. In the present study, it was not possible
to detect any difference in bone formation over time be-
tween the two treatment groups. There are several po-
tential reasons for this discrepancy. The distal radius
fracture was chosen in part because it is a common frac-
ture and because external fixation is a viable option for
stabilization, even though plate fixation has gained in
popularity over the last years. By using external fixation,
there was no metal at the fracture site, thereby assess-
ment of radiological healing could be done without dis-
turbance of hardware. In addition, fracture stability after
frame removal could be measured and used as an indir-
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Figure 6 Grip strength (mean with 95% CI).
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cated in the metaphysis which consists of spongious
bone with high healing potential due to extensive
vascularization. A distal radius fracture usually heals
rapidly, and delayed union is very unusual. One could
therefore argue that a metaphyseal fracture, like the dis-
tal radius fracture, already has such a high healing rate
that it hardly can be further accelerated. Based on this,
fractures in the diaphyseal bone would be more appro-
priate when efficacy of Augment® is investigated.
Furthermore, conventional radiography is a fairly blunt
tool for quantitative assessment of new bone formation
in a metaphyseal area, and the presence of calcium
phosphate particles in the product implanted at the frac-
ture site might be difficult to distinguish from the bone.
In addition, since only a limited number of radiographic
examinations can be allowed within a clinical study, a
subtle change in bone formation over time is difficult to
observe, and therefore, it is not possible to detect a small
difference in bone formation between the two groups.
Before injecting Augment® into the fracture gap, a small
void was created at the fracture site by impacting the
spongious bone inside the fracture with an elevator. This
impaction created less bone volume inside the cavity,
and more dense bone in the margins of the void, which,
together with calcium phosphate particles, made it more
difficult to assess the healing of the fractures in the
Augment® group. The impaction of bone could also have
increased the instability and delayed the bone healing in
the Augment® group. All fractures in the study were
treated with external fixation for 6 weeks. It is a com-
mon duration of treatment for distal radius fractures
and often leads to advanced healing without severe
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ation. We chose 6 weeks of treatment in order not to
compromise the position of the fractures, but by choos-
ing such a long fixation time, a potential acceleration of
healing and improved early fracture stability in the
Augment® group could have been missed.
The impaired wrist flexion in the Augment® group was
an unexpected finding that we believe was caused by the
dorsal incision used to get access to the fracture for
implanting the material and not an effect of the Augment®
per se. Despite that the incision was small, local scar tissue
and adhesions in the soft tissue on the dorsal side of the
wrist seem as the most plausible cause for the reduced
flexion. This can explain the observed restriction in motion
that involved only flexion, while wrist motion in other
directions did not differ between the treatment groups. If
the restricted movement had been caused by the
Augment®, it seems reasonable that some local soft tissue
reaction would have been visible. In comparison, when
implanting bone morphogenetic protein (BMP), it is known
that the implanted substance induces a local inflammatory
response that can include swelling of clinical importance
[16-18]. In contrast to the adverse effects reported for BMP,
there were no signs of inflammation in any of the Aug-
ment® patients in the present study.
The finding with significantly fewer pin site infections in
the Augment® group, 2/80 versus 18/80 in the control
group, was surprising and no reasonable explanation has
been identified. All factors that are known to reduce the
risk for pin site infections were kept constant in all patients,
which make it unlikely that this finding was due to a sys-
tematic error in the care or evaluation of the pin sites. In
previous studies, local application of a PDGF-BB containing
dressing to diabetic ulcers in the lower extremity have been
shown to significantly increase the incidence of complete
wound closure and time to healing [19], which is an ex-
pected outcome based upon the biologic mode of action of
rhPDGF-BB. As Augment®, in the present study, was ad-
ministered at the fracture site, and not at the pin site, there
is no obvious explanation to be found in a local soft tissue
effect by Augment®. The decrease in pin site infections
might instead be due to a reason not directly related to the
effect of PDGF-BB. For instance, a reduction in finger
movement and forearm rotation caused by pain from the
dorsal incision at the administration site in the Augment®
group could have had a protective effect against pin infec-
tion since less soft tissue motion around the pins will re-
duce the irritation in the surrounding soft tissue. In all, the
mechanism of a potential protective action against pin in-
fection by Augment® is unclear, although not inconsistent
with the established wound healing capacity of rhPDGF-
BB. In order to reveal a better understanding, this question
should be addressed in a study with pin site infection being
the primary outcome.Conclusions
rhPDGF-BB/β-TCP (Augment®) is safe and convenient
for local administration into wrist fractures. In this pilot
study, we could not detect any reduced healing time in
the Augment® group although potential efficacy should
be addressed in larger studies.
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